Onkologie. 2020:14(1):37-39 | DOI: 10.36290/xon.2020.010

Current perspective on the treatment of advanced pancreatic adenocarcinoma

Stanislav John

Klinika onkologie a radioterapie, FN Hradec Králové

Ústav lékařské biologie a genetiky, LF UK v Hradci Králové

The incidence of pancreatic ductal adenocarcinoma (PDAC) in the population of the Czech Republic as well as in other developed countries has been increasing continuously. What is even more serious, however, is the high mortality rate of this disease that remains nearly unchanged even in the setting of intensive treatment. The overall five-year survival is only 7-9% of patients. Near-future estimates mention PDAC as one of the leading causes of death from tumour disease. Thus, it is a very pressing global issue in contemporary oncology. Major advances not only in treatment, but also in early diagnosis of patients and prevention are vital.

Keywords: pancreatic tumour, epidemiology, treatment, stroma.

Received: February 11, 2020; Revised: February 11, 2020; Accepted: February 12, 2020; Prepublished online: February 12, 2020; Published: March 1, 2020  Show citation